Treatment resulted in significant clinical improvement, reduced sweat chloride concentrations, downregulation of routine serum inflammatory markers as well as a significant reduction in both CF serum and stimulated PBMCs IL-18, IL-1β, TNF and IL-6 levels. This evidence concerns the gene IL6 and cystic fibrosis.